Efecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemática

Vista sencilla de ítem
dc.contributor.advisorBecerra-Camargo, Jesus
dc.contributor.advisorCrosby, Milton Josué
dc.contributor.authorSierra Sánchez, Karen Tatiana
dc.contributor.researchgroupFortalecimiento Institucional de Servicios Farmacéuticosspa
dc.date.accessioned2022-03-08T15:27:36Z
dc.date.available2022-03-08T15:27:36Z
dc.date.issued2021-12-14
dc.descriptionilustraciones, graficas, diagramasspa
dc.description.abstractIntroducción: La enfermedad cardiovascular causa una de cada tres muertes en pacientes con diabetes mellitus tipo 2. La evidencia actual sobre los efectos de los fármacos antidiabeticos para controlar y reducir las complicaciones cardiovasculares es moderada y no concluyente. Objetivo: Determinar la efectividad y seguridad de la metformina y combinaciones con I-DPP4 y I-SGLT2, administrados por vía oral, como factor protector frente a enfermedades cardiovasculares. Metodología: Se realizo  una revisión en las bases de datos Medline, PubMed, y Cochrane Library utilizando términos específicos. La búsqueda se realizo  en ingles y español para el periodo de 2010 a 2020. La calidad de los estudios y el riesgo de sesgo fueron evaluados. Resultados: Se encontraron 911 publicaciones. Después de aplicar los criterios de inclusión y exclusión, fueron seleccionaron 13 documentos: 5 RTC, 2 estudios observacionales y otras 6 categorías (tres informes, dos RTC y una guía de diabetes). Se seleccionaron siete artículos para esta revisión. Conclusión: Esta revisión proporciona una visión general de la evidencia disponible hasta el momento sobre la eficacia y la seguridad del uso de metformina sola o en combinación de SGTL2 y I-DPP4 sobre el riego cardiovascular. Es necesario incluir nuevos estudios para actualizar el conocimiento de estas nuevas clases terapéutica utilizadas en el tratamiento de la diabetes mellitus tipo 2. Palabras clave: Diabetes mellitus tipo 2, Riesgo cardiovascular, antidiabeticos orales. (Texto tomado de la fuente)spa
dc.description.abstractEffect of the use of metformin and oral combinations in type II diabetes mellitus on the risk and prognosis of cardiovascular disease: Systematic review. Background: Cardiovascular disease causes one in three deaths in patients with type 2 diabetes mellitus. The current evidence on the effects of antidiabetic drugs to control and reduce cardiovascular complications is low and inconclusive. Aim: To determine the effectiveness and safety of metformin and combinations with I-DPP4 and I-SGLT2, administered orally, as a protective factor against cardiovascular diseases. Method: A review was made in the PubMed, PubMed and Cochrane Library databases using specific terms. The search was made in English and Spanish, looking for publications from 2010 to 2020. Study quality and risk of bias were also assessed. Results: 911 publications were found. After applying the inclusion and exclusion criteria, 13 documents were selected: 5 RTCs, 2 observational studies, and 6 other categories (three reports, two RTCs, and one diabetes guideline). Seven articles were selected for this review. Conclusion: This review provides an overview of the evidence available to date on the efficacy and safety of the use of metformin alone or in combination of I-SGLT2 and I-DPP4 on cardiovascular risk. It is necessary to include new studies to update the knowledge of these new therapeutic classes used in the treatment of type 2 diabetes mellitus. Keywords: Type 2 Diabetes Mellitus, cardiovascular risk, oral antidiabetics.eng
dc.description.degreelevelMaestríaspa
dc.description.degreenameMagíster en Ciencias - Farmacologíaspa
dc.description.researchareaUso racional de medicamentosspa
dc.format.extent93 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.identifier.instnameUniversidad Nacional de Colombiaspa
dc.identifier.reponameRepositorio Institucional Universidad Nacional de Colombiaspa
dc.identifier.repourlhttps://repositorio.unal.edu.co/spa
dc.identifier.urihttps://repositorio.unal.edu.co/handle/unal/81150
dc.language.isospaspa
dc.publisherUniversidad Nacional de Colombiaspa
dc.publisher.branchUniversidad Nacional de Colombia - Sede Bogotáspa
dc.publisher.departmentDepartamento de Farmaciaspa
dc.publisher.facultyFacultad de Cienciasspa
dc.publisher.placeBogotá, Colombiaspa
dc.publisher.programBogotá - Ciencias - Maestría en Ciencias - Farmacologíaspa
dc.relation.references1. Resources and tools [Internet]. [cited 2021 Oct 26]. Available from: https://www.idf.org/our-activities/advocacy-awareness/resources-and-tools/129-globaldiabetes- plan-2011-2021.htmlspa
dc.relation.references2. Situación de la enfermedad renal crónica, la hipertensión arterial y diabetes mellitus en Colombia 2020 | Cuenta de Alto Costo [Internet]. [cited 2021 Oct 27]. Available from: https://cuentadealtocosto.org/site/publicaciones/situacion-de-la-enfermedad-renalcronica- la-hipertension-arterial-y-diabetes-mellitus-en-colombia-2020/spa
dc.relation.references3. Dalama B, Mesa J. Nuevos hipoglucemiantes orales y riesgo cardiovascular. Cruzando la frontera metabólica. Revista Española de Cardiología [Internet]. 2016 Nov 1 [cited 2021 Oct 27];69(11):1088–97. Available from: http://www.revespcardiol.org/es-nuevoshipoglucemiantes- orales-riesgo-cardiovascular--articulo-S0300893216303785spa
dc.relation.references4. SM H, S L, T R, K P, M L. Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. The New England journal of medicine [Internet]. 1998 Jul 23 [cited 2021 Oct 27];339(4):229–34. Available from: https://pubmed.ncbi.nlm.nih.gov/9673301/spa
dc.relation.references5. María Del Pilar D, Sansone S. Antidiabéticos orales y riesgo cardiovascular María del Pilar Serra Sansone Antidiabéticos orales y riesgo cardiovascular Epidemiología de la diabetes y riesgo de enfermedad cardiovascular.spa
dc.relation.references6. La historia de la rosiglitazona: mensajes clave [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-endocrinologia-nutricion-12-pdf- S1575092210002469spa
dc.relation.references7. TM L, TF C. Impairment of myocardial protection in type 2 diabetic patients. The Journal of clinical endocrinology and metabolism [Internet]. 2003 Feb 1 [cited 2021 Oct 27];88(2):531–7. Available from: https://pubmed.ncbi.nlm.nih.gov/12574175/spa
dc.relation.references8. Páginas - Enfermedades cardiovasculares [Internet]. [cited 2021 Oct 27]. Available from: https://www.minsalud.gov.co/salud/publica/PENT/Paginas/enfermedadescardiovasculares. aspxspa
dc.relation.references9. A P, D M-W, UA M, R L, M N, G F, et al. Definition, Classification and Diagnosis of Diabetes Mellitus. Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association [Internet]. 2019 [cited 2021 Oct 27];127(S 01):S1–7. Available from: https://pubmed.ncbi.nlm.nih.gov/31860923/spa
dc.relation.references10. Atlas De La Diabetes De La Fid 9a Edici n 2019 [Internet]. [cited 2021 Oct 27]. Available from: https://diabetesatlas.org/es/spa
dc.relation.references11. Epidemiología de la diabetes en Colombia [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-avances-diabetologia-326-pdf-S1134323010620054spa
dc.relation.references12. Mata-Cases M, FernáNdez-Bertolín E, García-Dur  M, Cos-Claramunt X, Pareja-Rossell C, Pujol-Ribera E. doi:10.1016/j.gaceta.2008.05.007. GACETA Sanitaria. 23:133–8.spa
dc.relation.references13. Ruiz-García A, Arranz-Martínez E, García- Álvarez JC, García-Fernández ME, Palacios- Mart nez D, Montero-Costa A, et al. Prevalencia de diabetes mellitus en el  ámbito de la atención primaria española y su asociación con factores de riesgo cardiovascular y enfermedades cardiovasculares. Estudio SIMETAP-DM. Clínica e Investigación en Arteriosclerosis. 2020 Jan 1;32(1):15–26.spa
dc.relation.references14.  stenson CG. The pathophysiology of type 2 diabetes mellitus: An overview. Acta Physiologica Scandinavica. 2001;171(3):241–7.spa
dc.relation.references15. RJ H. Type-2 diabetes mellitus and cardiovascular disease. Future cardiology [Internet]. 2018 Nov 1 [cited 2021 Oct 27];14(6):491–509. Available from: https://pubmed.ncbi.nlm.nih.gov/30409037/spa
dc.relation.references16. Petrie JR, Guzik TJ, Touyz RM. Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. The Canadian Journal of Cardiology [Internet]. 2018 May 1 [cited 2021 Oct 27];34(5):575. Available from: /pmc/articles/PMC5953551/spa
dc.relation.references17. Complicaciones de la diabetes mellitus. Diagn stico y tratamiento [Internet]. [cited 2021 Oct 27]. Available from: https://www.elsevier.es/es-revista-medicina-familia-semergen-40- pdf-S1138359301739317spa
dc.relation.references18. Dr. Roberto González Dr. Edgar Mora Brito. ALAD. 2019 [cited 2021 Oct 27]; Available from: www.revistaalad.comspa
dc.relation.references19. ADA-Standards-of-Medical-Care-Diabetes-Care-2021. ADA-Standards-of-Medical-Care- Diabetes-Care-2021 [Internet]. [cited 2021 Dec 12]. Available from: https://www.fipec.net/wp-content/uploads/2021/04/ADA-Standards-of-Medical-Care- Diabetes-Care-2021.pdfspa
dc.relation.references20. Vista de Metformina: m s all  del control glucémico [Internet]. [cited 2021 Oct 27]. Available from: https://revistas.uis.edu.co/index.php/revistamedicasuis/article/view/6308/6532spa
dc.relation.references21. Alfonso Figueredo E, Andrés Reyes Sanamé  F, Luisa Pérez  Álvarez M, Batista Acosta Y, Pe a Garcell Hospital General Docente Y, Luis Fernández Hernández Baquero G. Inhibidores de la dipeptidil peptidasa 4 y una nueva estrategia farmacológica en la diabetes mellitus tipo 2 Inhibitors of dipeptidil peptidase 4 new pharmacologic strategic in the diabetes mellitus type 2. Revista Cubana de Medicina [Internet]. 2016 [cited 2021 Oct 27];55(3). Available from: http://scielo.sld.cuspa
dc.relation.references22. Revista Cubana de Endocrinología. 2020(Sep-Dic);31(3):e250. [cited 2021 Oct 27]; Available from: https://orcid.org/0000-0001-5163--8045spa
dc.relation.references23. Versión 5.1.0. [cited 2021 Oct 27]; Available from: www.cochrane-handbook.org.spa
dc.relation.references24. Fau C, Nabzo S. Metaan lisis: bases conceptuales, análisis e interpretación estadística Meta-analysis: Conceptual bases, statistical analysis and interpretation. Rev Mex Oftalmol [Internet]. 2020 [cited 2021 Dec 12];94(6):260–73. Available from: www.rmo.com.mxspa
dc.relation.references25. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD. European Heart Journal. 2020 Jan 1;41(2):255–323.spa
dc.relation.references26. Bethel MA, Green JB, Milton J, Tajar A, Engel SS, Califf RM, et al. Regional, age and sex differences in baseline characteristics of patients enrolled in the Trial Evaluating Cardiovascular Outcomes with Sitagliptin (TECOS). Diabetes, Obesity and Metabolism. 2015 Apr 1;17(4):395–402.spa
dc.relation.references27. Terenzi DC, Verma S, Trac JZ, Quan A, Mason T, Al-Omran M, et al. P317A novel role of SGLT2 inhibitors to increase circulating proangiogenic progenitor cells in patients with type 2 diabetes and cardiovascular disease: A sub-study of the EMPA-HEART CardioLink-6 Trial. European Heart Journal [Internet]. 2019 Oct 1 [cited 2021 Oct 30];40(Supplement_1). Available from: https://academic.oup.com/eurheartj/article/40/Supplement_1/ehz747.0152/5594325spa
dc.relation.references28. Conference Abstract - A diabetes risk score for cardiovascular events in primary and secondary prevention: Observations from the SAVOR-TIMI 53 study [Internet]. [cited 2021 Oct 30]. Available from: https://www.mdlinx.com/surgery/conferenceabstract. cfm/52401/?nonus=0&searchstring=&coverage_day=0&page=2spa
dc.relation.references29. N I, H O, H S, N F, S K, K K. SYR-472, a novel once-weekly dipeptidyl peptidase-4 (DPP-4) inhibitor, in type 2 diabetes mellitus: a phase 2, randomised, double-blind, placebocontrolled trial. The lancet Diabetes & endocrinology [Internet]. 2014 Feb [cited 2021 Oct 30];2(2):125–32. Available from: https://pubmed.ncbi.nlm.nih.gov/24622716/spa
dc.relation.references30. CE C, KC U, TH C, TH L, YJ W, KL W, et al. 2020 Consensus of Taiwan Society of Cardiology on the pharmacological management of patients with type 2 diabetes and cardiovascular diseases. Journal of the Chinese Medical Association : JCMA [Internet]. 2020 Jul 1 [cited 2021 Oct 30];83(7):587–621. Available from: https://pubmed.ncbi.nlm.nih.gov/32628427/spa
dc.relation.references31. Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1504720 [Internet]. 2015 Nov 25 [cited 2021 Oct 27];13(1):17–8. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1504720spa
dc.relation.references32. McMurray JJV, Solomon SD, Inzucchi SE, K ber L, Kosiborod MN, Martinez FA, et al. Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction. https://doi.org/101056/NEJMoa1911303 [Internet]. 2019 Sep 19 [cited 2021 Oct 92 27];381(21):1995–2008. Available from: https://www.nejm.org/doi/full/10.1056/NEJMoa1911303spa
dc.relation.references33. Rosenstock J, Perkovic V, Johansen OE, Cooper ME, Kahn SE, Marx N, et al. Effect of Linagliptin vs Placebo on Major Cardiovascular Events in Adults With Type 2 Diabetes and High Cardiovascular and Renal Risk: The CARMELINA Randomized Clinical Trial. JAMA [Internet]. 2019 Jan 1 [cited 2021 Oct 27];321(1):69–79. Available from: https://jamanetwork.com/journals/jama/fullarticle/2714646spa
dc.relation.references34. Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, et al. Saxagliptin and Cardiovascular Outcomes in Patients with Type 2 Diabetes Mellitus. http://dx.doi.org/101056/NEJMoa1307684 [Internet]. 2013 Oct 2 [cited 2021 Oct 27];369(14):1317–26. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1307684spa
dc.relation.references35. Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. http://dx.doi.org/101056/NEJMoa1501352 [Internet]. 2015 Jul 15 [cited 2021 Oct 27];373(3):232–42. Available from: https://www.nejm.org/doi/full/10.1056/nejmoa1501352spa
dc.relation.references36. Turner R. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). The Lancet [Internet]. 1998 Sep 12 [cited 2021 Oct 27];352(9131):854–65. Available from: http://www.thelancet.com/article/S0140673698070378/fulltextspa
dc.relation.references37. Lee K-T, Yeh Y-H, Chang S-H, See L-C, Lee C-H, Wu L-S, et al. Metformin is associated with fewer major adverse cardiac events among patients with a new diagnosis of type 2 diabetes mellitus: A propensity score-matched nationwide study. Medicine [Internet]. 2017 Jul 1 [cited 2021 Oct 27];96(28). Available from: /pmc/articles/PMC5515773/spa
dc.relation.references38. Asociación entre la edad del diagnóstico de diabetes tipo 2 y la gravedad del trastorno. Revista Panamericana de Salud Pública. 2003 Dec;14(6):434–5.spa
dc.relation.references39. Wilcox T, de Block C, Schwartzbard AZ, Newman JD. Diabetic Agents, From Metformin to SGLT2 Inhibitors and GLP1 Receptor Agonists: JACC Focus Seminar. Journal of the American College of Cardiology. 2020 Apr 28;75(16):1956–74.spa
dc.relation.references40. Palmer SC, Tendal B, Mustafa RA, Vandvik PO, Li S, Hao Q, et al. Sodium-glucose cotransporter protein-2 (SGLT-2) inhibitors and glucagon-like peptide-1 (GLP-1) receptor agonists for type 2 diabetes: systematic review and network meta-analysis of randomised controlled trials. The BMJ [Internet]. 2021 Jan 13 [cited 2021 Oct 30];372. Available from: /pmc/articles/PMC7804890/spa
dc.relation.references41. Nunes JPL, Rodrigues JD, Mel o F. Acute myocardial infarction associated to DPP-4 inhibitors. Heart, Lung and Vessels [Internet]. 2014 [cited 2021 Oct 30];6(3):180. Available from: /pmc/articles/PMC4181279/spa
dc.relation.references42. Zheng SL, Roddick AJ, Aghar-Jaffar R, Shun-Shin MJ, Francis D, Oliver N, et al. Association Between Use of Sodium-Glucose Cotransporter 2 Inhibitors, Glucagon-like Peptide 1 93 Agonists, and Dipeptidyl Peptidase 4 Inhibitors With All-Cause Mortality in Patients With Type 2 Diabetes: A Systematic Review and Meta-analysis. JAMA [Internet]. 2018 Apr 17 [cited 2021 Oct 30];319(15):1580. Available from: /pmc/articles/PMC5933330/spa
dc.relation.references43. Scheen AJ. Cardiovascular Effects of New Oral Glucose-Lowering Agents: DPP-4 and SGLT-2 Inhibitors. Circulation Research [Internet]. 2018 May 1 [cited 2021 Oct 30];122(10):1439. Available from: /pmc/articles/PMC5959222/spa
dc.relation.references44. Galvus | European Medicines Agency [Internet]. [cited 2021 Dec 12]. Available from: https://www.ema.europa.eu/en/medicines/human/EPAR/galvusspa
dc.relation.references45. Davies MJ, D’Alessio DA, Fradkin J, Kernan WN, Mathieu C, Mingrone G, et al. Management of hyperglycaemia in type 2 diabetes, 2018. A consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia 2018 61:12 [Internet]. 2018 Oct 5 [cited 2022 Jan 28];61(12):2461–98. Available from: https://link.springer.com/article/10.1007/s00125-018-4729-5spa
dc.relation.references46. Foretz M, Guigas B, Bertrand L, Pollak M, Viollet B. Metformin: From Mechanisms of Action to Therapies. Cell Metabolism [Internet]. 2014 Dec 2 [cited 2022 Jan 29];20(6):953–66. Available from: http://www.cell.com/article/S1550413114004410/fulltextspa
dc.relation.references47. Madiraju AK, Erion DM, Rahimi Y, Zhang XM, Braddock DT, Albright RA, et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature [Internet]. 2014 [cited 2022 Jan 29];510(7506):542. Available from: /pmc/articles/PMC4074244/spa
dc.relation.references48. Foretz M, Guigas B, Viollet B. Understanding the glucoregulatory mechanisms of metformin in type 2 diabetes mellitus. Nature Reviews Endocrinology [Internet]. 2019 Aug 22 [cited 2022 Jan 29];15(10):569–89. Available from: https://www.hal.inserm.fr/inserm-02277186spa
dc.relation.references49. Bromage DI, Godec TR, Pujades-Rodriguez M, Gonzalez-Izquierdo A, Denaxas S, Hemingway H, et al. Metformin use and cardiovascular outcomes after acute myocardial infarction in patients with type 2 diabetes: a cohort study. Cardiovascular Diabetology [Internet]. 2019 Dec 9 [cited 2021 Oct 30];18(1). Available from: /pmc/articles/PMC6900858/spa
dc.relation.references50. Conceptos fundamentales de las revisiones sistemáticas/metaanálisis [Internet]. [cited 2021 Dec 12]. Available from: https://www.elsevier.es/es-revista-urologia-colombiana-398- pdf-S0120789X15000076spa
dc.relation.references51. Gamble J-M, Thomas JM, Twells LK, Midodzi WK, Majumdar SR. Comparative effectiveness of incretin-based therapies and the risk of death and cardiovascular events in 38,233 metformin monotherapy users. Medicine [Internet]. 2016 Jun 1 [cited 2021 Oct 30];95(26). Available from: /pmc/articles/PMC4937919/spa
dc.rights.accessrightsinfo:eu-repo/semantics/openAccessspa
dc.rights.licenseReconocimiento 4.0 Internacionalspa
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/spa
dc.subject.ddc610 - Medicina y saludspa
dc.subject.decsMetforminaeng
dc.subject.decsMetformineng
dc.subject.decsDiabetes Mellitusspa
dc.subject.decsDiabetes Mellituseng
dc.subject.decsRevisiónspa
dc.subject.decsRevieweng
dc.subject.proposalDiabetes mellitus tipo 2spa
dc.subject.proposalRiesgo cardiovascularspa
dc.subject.proposalType 2 Diabetes Mellituseng
dc.subject.proposalCardiovascular riskeng
dc.subject.proposalOral antidiabeticseng
dc.subject.proposalAntidiabeticos oralesspa
dc.titleEfecto del uso de metformina y combinaciones orales en diabetes mellitus tipo II sobre el riesgo y pronóstico de la enfermedad cardiovascular: revisión sistemáticaspa
dc.title.translatedEffect of the use of metformin and combinations in type II diabetes mellitus on the risk and prognosis of cardiovascular diseases: systematic revieweng
dc.typeTrabajo de grado - Maestríaspa
dc.type.coarhttp://purl.org/coar/resource_type/c_bdccspa
dc.type.coarversionhttp://purl.org/coar/version/c_ab4af688f83e57aaspa
dc.type.contentTextspa
dc.type.driverinfo:eu-repo/semantics/masterThesisspa
dc.type.redcolhttp://purl.org/redcol/resource_type/TMspa
dc.type.versioninfo:eu-repo/semantics/acceptedVersionspa
dcterms.audience.professionaldevelopmentEstudiantesspa
dcterms.audience.professionaldevelopmentInvestigadoresspa
oaire.accessrightshttp://purl.org/coar/access_right/c_abf2spa

Archivos

Bloque original

Mostrando 1 - 1 de 1
Miniatura
Nombre:
53161452.2021.pdf
Tamaño:
2.24 MB
Formato:
Adobe Portable Document Format
Descripción:
Tesis de Maestría en Ciencias - Farmacología
Descargar

Bloque de licencias

Mostrando 1 - 1 de 1
Miniatura
Nombre:
license.txt
Tamaño:
3.98 KB
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Maestría en Ciencias - Farmacología